Read Full Article
Elizabeth McKee Anderson has also been appointed to Context's board of directors , bringing more than 30 years of industry leadership in ...
Today marks a major step forward for Context as we transform from an early to clinical-stage biopharmaceutical company.
I look forward to working with Context and helping the company advance its strategy to develop drugs to treat hormone-responsive cancers. This is an area of significant unmet need.
I am excited to join Context's board and bring my extensive strategic and portfolio-building experience to Context as it continues to grow.